FCMI
FULC icon

Foresite Capital Management IV’s Fulcrum Therapeutics FULC Stock Holding History

Foresite Capital Management IV’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,133,948
Closed -$20.7M – 16
2020
Q2 		$20.7M Buy
1,133,948
+135,293
+14% +$2.13M 10.1% 4
2020
Q1 		$11.9M Sell
998,655
-501,345
-33% -$8.02M 14.7% 3
2019
Q4 		$25M Sell
1,500,000
-187,500
-11% -$1.79M 10.77% 5
2019
Q3 		$11.2M Buy
+1,687,500
New +$18.7M 3.62% 12

Other funds holding FULC

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Foresite Capital Management IV's FULC Position: Q3 2020 in Review

Foresite Capital Management IV sold out of Fulcrum Therapeutics (FULC) in Q3 2020, closing a stake of 1,133,948 shares — an estimated $20.7M sold.

Foresite Capital Management IV first reported a position in FULC in Q3 2019 and held it in 4 quarters. The position peaked at $25M in Q4 2019. 55 funds tracked by Wall St. Rank hold FULC as of Q3 2020.

  • Foresite Capital Management IV reported no remaining Fulcrum Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Foresite Capital Management IV sold 1,133,948 Fulcrum Therapeutics shares in Q3 2020, an estimated $20.7M.
  • Foresite Capital Management IV first reported a position in Fulcrum Therapeutics in Q3 2019 and held it in 4 quarters.
  • Foresite Capital Management IV's Fulcrum Therapeutics position peaked at $25M in Q4 2019.
  • 55 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2020.

Based on Foresite Capital Management IV's 13F filing for Q3 2020, filed 13 Nov 2020.